These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26566278)

  • 1. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
    Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
    Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
    BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Claudin expression in breast cancer: high or low, what to expect?
    Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J
    Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
    Choi J; Jung WH; Koo JS
    Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Claudins as prognostic factors of breast cancer].
    Szász MA
    Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.
    Lu S; Singh K; Mangray S; Tavares R; Noble L; Resnick MB; Yakirevich E
    Mod Pathol; 2013 Apr; 26(4):485-95. PubMed ID: 23222490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
    Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
    Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
    Gerhard R; Ricardo S; Albergaria A; Gomes M; Silva AR; Logullo ÂF; Cameselle-Teijeiro JF; Paredes J; Schmitt F
    Breast; 2012 Jun; 21(3):354-60. PubMed ID: 22464177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile.
    Yen TY; Bowen S; Yen R; Piryatinska A; Macher BA; Timpe LC
    J Proteome Res; 2017 Apr; 16(4):1391-1400. PubMed ID: 28287265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct claudin expression characterizes BRCA1-related breast cancer.
    Heerma van Voss MR; van Diest PJ; Smolders YH; Bart J; van der Wall E; van der Groep P
    Histopathology; 2014 Dec; 65(6):814-27. PubMed ID: 25041042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic and prognosis features of Claudin-low breast cancers].
    Xu J; Lan KT; Su TH; Li ZF; Wan Y; Gu QQ; Zou PC; Zou X
    Zhonghua Bing Li Xue Za Zhi; 2017 Sep; 46(9):634-639. PubMed ID: 28910875
    [No Abstract]   [Full Text] [Related]  

  • 13. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
    Jääskeläinen A; Soini Y; Jukkola-Vuorinen A; Auvinen P; Haapasaari KM; Karihtala P
    BMC Cancer; 2018 Feb; 18(1):223. PubMed ID: 29482498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
    Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
    Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype.
    Rito M; Schmitt F; Pinto AE; André S
    Virchows Arch; 2014 Aug; 465(2):185-91. PubMed ID: 24903673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-Low Breast Cancer; Clinical & Pathological Characteristics.
    Dias K; Dvorkin-Gheva A; Hallett RM; Wu Y; Hassell J; Pond GR; Levine M; Whelan T; Bane AL
    PLoS One; 2017; 12(1):e0168669. PubMed ID: 28045912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
    Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF;
    Cancer Invest; 2018; 36(7):378-388. PubMed ID: 30142017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.